Photodynamic Therapy and Immune Checkpoint Blockade†
Open Access
- 1 September 2020
- journal article
- review article
- Published by Wiley in Photochemistry and Photobiology
- Vol. 96 (5), 954-961
- https://doi.org/10.1111/php.13300
Abstract
Immune checkpoints including PD-1 and CTLA-4 help to regulate the intensity and timeframe of the immune response. Since they become upregulated in cancer and prevent sufficient antitumor immunity, monoclonal antibodies against these checkpoints have shown clinical promise for a range of cancers. Multimodal treatment plans combining immune checkpoint inhibitors with other therapies, including photodynamic therapy (PDT), may help to expand treatment efficacy and minimize side effects. PDT's cytotoxic effects are spatially limited by the light activation process, constraining PDT direct effects to the treatment field. The production of damage-associated molecular patterns and tumor-associated antigens from PDT can encourage accumulation and maturation of antigen-presenting cells and reprogram the tumor microenvironment to be more susceptible to therapies targeting immune checkpoints.Funding Information
- University of Pennsylvania
This publication has 57 references indexed in Scilit:
- The diverse functions of the PD1 inhibitory pathwayNature Reviews Immunology, 2017
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionCell Reports, 2017
- Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathwayGut, 2017
- Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cellsImmunology Letters, 2017
- Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancerGut, 2016
- CTLA-4 and PD-1 PathwaysAmerican Journal of Clinical Oncology, 2016
- The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic InfectionImmunity, 2014
- Programmed Death Ligand 2 in Cancer-Induced Immune SuppressionJournal of Immunology Research, 2012
- PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages duringchronic hepatitis C virus infectionImmunology, 2010
- The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its LigandsThe Journal of Immunology, 2008